These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22074713)

  • 1. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.
    Kahn JG; Marseille E; Moore D; Bunnell R; Were W; Degerman R; Tappero JW; Ekwaru P; Kaharuza F; Mermin J
    BMJ; 2011 Nov; 343():d6884. PubMed ID: 22074713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.
    Mermin J; Ekwaru JP; Were W; Degerman R; Bunnell R; Kaharuza F; Downing R; Coutinho A; Solberg P; Alexander LN; Tappero J; Campbell J; Moore DM
    BMJ; 2011 Nov; 343():d6792. PubMed ID: 22074711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.
    Hyle EP; Jani IV; Rosettie KL; Wood R; Osher B; Resch S; Pei PP; Maggiore P; Freedberg KA; Peter T; Parker RA; Walensky RP
    AIDS; 2017 Sep; 31(15):2135-2145. PubMed ID: 28906279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
    Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
    AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
    Medina Lara A; Kigozi J; Amurwon J; Muchabaiwa L; Nyanzi Wakaholi B; Mujica Mota RE; Walker AS; Kasirye R; Ssali F; Reid A; Grosskurth H; Babiker AG; Kityo C; Katabira E; Munderi P; Mugyenyi P; Hakim J; Darbyshire J; Gibb DM; Gilks CF;
    PLoS One; 2012; 7(4):e33672. PubMed ID: 22545079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project.
    Okoboi S; Ekwaru PJ; Campbell JD; Egessa A; King R; Bakanda C; Muramuzi E; Kaharuza F; Malamba S; Moore DM
    BMC Public Health; 2016 Feb; 16():101. PubMed ID: 26830678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.
    Belaunzarán-Zamudio PF; Caro-Vega YN; Shepherd BE; Crabtree-Ramírez BE; Luz PM; Grinsztejn B; Cesar C; Cahn P; Cortés C; Wolff M; Pape JW; Padgett D; Gotuzzo E; McGowan C; Sierra-Madero JG;
    Bull World Health Organ; 2015 Aug; 93(8):529-39. PubMed ID: 26478610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
    Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
    PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
    Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
    Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of antiretroviral therapy based on the 2015 WHO guidelines.
    Kuznik A; Iliyasu G; Habib AG; Musa BM; Kambugu A; Lamorde M
    AIDS; 2016 Nov; 30(18):2865-2873. PubMed ID: 27662547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.
    Sempa J; Ssennono M; Kuznik A; Lamorde M; Sowinski S; Semeere A; Hermans S; Castelnuovo B; Manabe YC
    BMC Public Health; 2012 Sep; 12():736. PubMed ID: 22943068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
    Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
    Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.